← Back to Clinical Trials
Recruiting NCT07119060

NCT07119060 Ablative Technique For Ovarian Preservation In Endometrioma

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07119060
Status Recruiting
Phase
Sponsor Clinique Tivoli Ducos
Condition Endometrioma
Study Type INTERVENTIONAL
Enrollment 332 participants
Start Date 2025-09-18
Primary Completion 2034-07

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age 43 Years
Study Type INTERVENTIONAL
Interventions
Cystectomyplasma vaporizationSclerotherapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 332 participants in total. It began in 2025-09-18 with a primary completion date of 2034-07.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to compare pregnancy rates after different surgical treatments for endometriomas in adult women who have one or more ovarian cysts (endometriomas) larger than 2 cm requiring surgery. The main questions it aims to answer are: How many women become pregnant within 24 months after surgery ? What are the birth rates and different types of pregnancies (natural, with fertility treatments, and those continuing beyond 12 weeks)? How often do the endometriomas come back after surgery? What surgery-related complications occur? How do pain levels change after treatment? Researchers will compare different surgical treatment groups to see if one approach results in better pregnancy outcomes and fewer complications. Participants will: Be randomly assigned to different surgical treatment groups Undergo surgery for their endometriomas and endometriosis Attend follow-up visits at 3 months and 24 months after the procedure Have their pregnancy outcomes, pain levels, and potential complications monitored throughout the study period

Eligibility Criteria

Inclusion Criteria: * Patient aged between 18 and 43 years (inclusive) * Patient diagnosed with endometriosis (by histology or imaging) and symptomatic, requiring surgery (pelvic pain and/or infertility and/or risk to an organ) * Pelvic MRI or ultrasound performed within the last year showing at least one endometrioma larger than 20 mm in diameter * Patient with an intention to conceive (probable or certain) after surgery * Patient informed and having signed the consent form * Patient covered by a social security scheme Exclusion Criteria: * Intraoperative finding that the cyst is not an endometrioma * Patient under guardianship, conservatorship, or incapable of giving consent * Patient without sufficient understanding of the French language * Patient under judicial protection measures * Patient who is pregnant or breastfeeding

Contact & Investigator

Central Contact

Clotilde HUET

✉ recherche@ifemendo.fr

📞 +33 7 85 30 63 45

Principal Investigator

Horace ROMAN

STUDY DIRECTOR

IFEMEndo - Clinique Tivoli

Frequently Asked Questions

Who can join the NCT07119060 clinical trial?

This trial is open to female participants only, aged 18 Years or older, up to 43 Years, studying Endometrioma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07119060 currently recruiting?

Yes, NCT07119060 is actively recruiting participants. Contact the research team at recherche@ifemendo.fr for enrollment information.

Where is the NCT07119060 trial being conducted?

This trial is being conducted at Bordeaux, France.

Who is sponsoring the NCT07119060 clinical trial?

NCT07119060 is sponsored by Clinique Tivoli Ducos. The principal investigator is Horace ROMAN at IFEMEndo - Clinique Tivoli. The trial plans to enroll 332 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology